A Case Report of Successful Treatment With Crizotinib to Overcome Resistance to Osimertinib in an EGFR Mutated Non-Small-Cell Lung Cancer Patient Harboring an Acquired MET Exon 14 Mutation

Clin Lung Cancer. 2022 Mar;23(2):e131-e134. doi: 10.1016/j.cllc.2021.06.002. Epub 2021 Jun 13.
No abstract available

Keywords: METex14 skipping mutation; Resistance to osimertinib; Response to crizotinib; T790M positive Non–small-cell lung cancer.

Publication types

  • Case Reports

MeSH terms

  • Acrylamides / therapeutic use
  • Aniline Compounds / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Crizotinib / therapeutic use*
  • Drug Resistance, Neoplasm / drug effects
  • ErbB Receptors / metabolism
  • Humans
  • Lung Neoplasms / diet therapy*
  • Lung Neoplasms / genetics
  • Male
  • Mutation

Substances

  • Acrylamides
  • Aniline Compounds
  • osimertinib
  • Crizotinib
  • EGFR protein, human
  • ErbB Receptors